CORRECTING and REPLACING DPT Laboratories, Confab Announce Integration
SAN ANTONIO--(BUSINESS WIRE)--In seventh graf, name of United States licensor should read Food & Drug Administration (sted Federal Drug Administration).
“DPT’s sales and marketing team has a proven track record for building client relationships and driving growth”
The corrected release reads:
DPT LABORATORIES, CONFAB ANNOUNCE INTEGRATION
Pharmaceutical contract development and manufacturing organizations (CDMOs) DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, today announced the integration of the organizations under the leadership of Paul Johnson, Group President and COO.
The integration includes a re-branding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s established sales and marketing team to introduce Confab’s specialized expertise in complex solid, semi-solid and liquid dosage forms to new pharmaceutical industry clients, especially in the U.S. market.
The management teams for both companies will remain in place, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson.
“Confab is one of the most-respected pharmaceutical outsourcing organizations in Canada, with more than 30 years’ experience in manufacturing, packaging and analyzing a wide range of projects for both large and small pharmaceutical companies,” said Johnson.
“The integration will provide our sales team with complimentary manufacturing capabilities and a broader range of services to offer to our customers,” he added. “At the same time, the increased marketing support will leverage the continued investment Confab has made in infrastructure and capabilities, paying dividends in new client development and increased sales growth.”
Confab has 350 employees and a 140,000-square-foot, cGMP-compliant turnkey facility, which is licensed by the Health Canada Therapeutic Products Directorate, as well as the United States Food & Drug Administration.
“DPT’s sales and marketing team has a proven track record for building client relationships and driving growth,” said Brisson. “For our team at Confab, this will mean broader recognition of our capabilities and services, access to new markets and increased opportunities for growth.”
DPT, the industry leader for semi-solids and liquids, has research and development as well as manufacturing facilities in San Antonio, TX, as well as in Lakewood, N.J., where it is expanding its presence in the sterile and specialty products markets.
About DPT Laboratories
DPT is a contract development and manufacturing organization (CDMO) providing companies the best solutions to their sterile and non-sterile drug development and manufacturing needs through innovation, technology and service. Specializing in semi-solid and liquid dosage forms, DPT has a reputation for quality, unmatched technical expertise, extensive manufacturing capabilities and an exemplary regulatory compliance record. With five cGMP facilities, including R&D, manufacturing and packaging operations in San Antonio and Lakewood, N.J., DPT offers full service outsourcing solutions. For more information, call 210-476-8100 or visit www.DPTLabs.com.
Founded in 1979, Confab Inc. is a leading FDA-approved contract manufacturer to the pharmaceutical industry offering turnkey solutions for manufacturing and packaging clinical and commercial solid, liquid, and semi-solid products. Confab is located in Saint-Hubert, Quebec. More information about Confab can be found at www.confab.com.
About Renaissance Acquisition Holdings
Renaissance Acquisition Holdings focuses on two pharmaceutical industry segments in the United States and Canada: 1) contract development and manufacturing, and 2) commercialization of branded and generic prescription products. For more information visit www.RenaissanceAH.com.
About RoundTable Healthcare Partners
RoundTable Healthcare Partners, Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise. RoundTable has established a successful track record of working with owner/founders, family companies, management teams, entrepreneurs and corporate partners who share a vision and believe in the value creation potential of its partnership model. RoundTable currently manages $1.9 billion in capital, including three equity funds totaling $1.5 billion and two subordinated debt funds totaling $400 million. More information about RoundTable Healthcare Partners can be found at www.roundtablehp.com